Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
- May 18th, 2023
- 353 views
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance.
Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price target of $60 by Truist. In pre-market trading, $ACLX is currently trading at $41.34, with a slight increase of $0.10 (+0.24%).
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has received a Buy rating from Canaccord Genuity, along with a price target of $48. $PLRX is trading at $21.75 in pre-market, showing a gain of $0.22 (+1.02%).
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has been initiated with a Buy rating by Guggenheim. In pre-market trading, $TARS is trading at $16.41, experiencing a significant increase of $0.48 (+3.01%).
Varonis Systems, Inc. (Nasdaq: VRNS) has received a Buy rating and a price target of $30 from DA Davidson. However, in pre-market trading, $VRNS is currently trading at $22.81, facing a decrease of $1.20 (-5.00%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login